-
1Academic Journal
Authors: A. D. Karpenko, T. D. Vaitko, A. V. Tuzikov, A. M. Andrianov, А. Д. Карпенко, Т. Д. Войтко, А. В. Тузиков, А. М. Андрианов
Contributors: Работа выполнена при поддержке Государственной программы научных исследований «Конвергенция 2025» (подпрограмма «Междисциплинарные исследования и новые технологии», задание 3.04.1).
Source: Informatics; Том 20, № 3 (2023); 7-20 ; Информатика; Том 20, № 3 (2023); 7-20 ; 2617-6963 ; 1816-0301
Subject Terms: хронический миелоидный лейкоз, deep learning, generative neural networks, hetero-encoders, Bcr-Abl tyrosine kinase, molecular docking, anticancer drugs, chronic myeloid leukemia, глубокое обучение, генеративные нейронные сети, гетероэнкодеры, Bcr-Abl тирозинкиназа, молекулярный докинг, противоопухолевые препараты
File Description: application/pdf
Relation: https://inf.grid.by/jour/article/view/1259/1057; https://inf.grid.by/jour/article/downloadSuppFile/1259/266; https://inf.grid.by/jour/article/downloadSuppFile/1259/267; https://inf.grid.by/jour/article/downloadSuppFile/1259/268; https://inf.grid.by/jour/article/downloadSuppFile/1259/269; Vamathevan J., Clark D., Czodrowski P., Dunham I., Ferran E., ., Zhao S. Applications of machine learning in drug discovery and development. Nature Reviewers. Drug Discovery, 2019, vol. 18, no. 6, pp. 463-477. https://doi.org/10.1038/s41573-019-0024-5; Lipinski C. F., Maltarollo V. G., Oliveira P. R., da Silva A. B. F., Honorio K. M. Advances and perspectives in applying deep learning for drug design and discovery. Frontiers in Robotics and AI, 2019, vol. 6, art. 108. Available at: https://www.frontiersin.org/artides/10.3389/frobt.2019.00108/full (accessed 07.08.2023). https://doi.org/10.3389/frobt.2019.00108; Cramer P. AlphaFold2 and the future of structural biology. Nature Structural & Molecular Biology, 2021, vol. 28, no. 9, pp. 704-705.; Bryant P., Pozzati G., Elofsson A. Improved prediction of protein-protein interactions using AlphaFold2. Nature Communications, 2022, vol. 13, no. 1, art. 1265. Available at: https://www.nature.com/articles/s41467-022-29480-5 (accessed 07.08.2023). https://doi.org/10.1038/s41467-022-29480-5; David A., Islam S., Tankhilevich E., Sternberg M. J. The AlphaFold database of protein structures: a biologist's guide. Journal of Molecular Biology, 2022, vol. 434, no. 2, p. 167336.; Timmons P. B., Hewage C. M. ENNAVIA is a novel method which employs neural networks for antiviral and anti-coronavirus activity prediction for therapeutic peptides. Briefings in Bioinformatics, 2021, vol. 22, iss. 6, art. bbab258. Available at: https://academic.oup.com/bib/article/22/6/bbab258/6326528 (accessed 07.08.2023). https://doi.org/10.1093/bib/bbab258; Andrianov A. M., Nikolaev G. I., Shuldov N. A., Bosko I. P., Anischenko A. I., Tuzikov A. V. Application of deep learning and molecular modeling to identify small drug-like compounds as potential HIV-1 entry inhibitors. Journal if Biomolecular Structure and Dynamics, 2022, vol. 40, no. 16, pp. 7555-7573. https://doi.org/10.1080/07391102.2021.1905559; Zhang Y., Ye T., Xi H., Juhas M., Li J. Deep learning driven drug discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2. Frontiers in Microbiology, 2021, vol. 12. Available at: https://www.frontiersin.org/articles/10.3389/fmicb.2021.739684/full (accessed 07.08.2023). https://doi.org/10.3389/fmicb.2021.739684; Stokes J. M., Yang K., Swanson K., Jin W., Cubillos-Ruiz A., ., Collins J. J. A deep learning approach to antibiotic discovery. Cell, 2020, vol. 180, no. 4, art. e13, pp. 688-702. https://doi.org/10.1016/j.cell.2020.01.021; Mercado R., Rastemo T., Lindelof E., Klambauer G., Engkvist O., Bjerrum E. J. Practical notes on building molecular graph generative models. ChemRxiv, 2020. Available at: https://chemrxiv.org/engage/chemrxiv/article-details/60c74f55567dfe705bec5672 (accessed 07.08.2023). https://doi.org/10.26434/chemrxiv.12888383; Arús-Pous J., Blaschke T., Ulander S., Reymond J. L., Chen H., Engkvist O. Exploring the GDB-13 chemical space using deep generative models. Journal of Cheminformatics, 2019, vol. 11, art. 20. Available at: https://jcheminf.biomedcentral.com/articles/10.1186/s13321-019-0341-z (accessed 07.08.2023). https://doi.org/10.1186/s13321-019-0341-z; Prykhodko O., Johansson S. V., Kotsias P. C., Arus-Pous J., Bjerrum E. J., ., Chen H. A de novo molecular generation method using latent vector based generative adversarial network. Journal of Cheminformatics, 2019, vol. 11, no 1, art. 74. Available at: https://jcheminf.biomedcentral.com/articles/10.1186/s13321-019-0397-9 (accessed 07.08.2023). https://doi.org/10.1186/s13321-019-0397-9; Polykovskiy D., Zhebrak A., Vetrov D., Ivanenkov Y., Aladinskiy V., ., Kadurin A. Entangled conditional adversarial autoencoder for de novo drug discovery. Molecular Pharmaceutics, 2018, vol. 15, no. 10, pp. 4398-4405. https://doi.org/10.1021/acs.molpharmaceut.8b00839s; Zhang J., Mercado R., Engkvist O., Chen H. Comparative study of deep generative models on chemical space coverage. Journal of Chemical Information and Modeling, 2021, vol. 61, no. 6, pp. 2572-2581. https://doi.org/10.26434/chemrxiv.13234289.v1; Zhavoronkov A., Ivanenkov Y. A., Aliper A., Veselov M. S., Aladinskiy V. A., ., Aspuru-Guzik A. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 2019, vol. 37, no. 9, pp. 1038-1040. https://doi.org/10.1038/s41587-019-0224-x; Kostler W. J., Zielinski C. C. Targeting receptor tyrosine kinases in cancer. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. New York, Springer, 2015, pp. 225-278.; Kantarjian H. M., Hochhaus A., Saglio G., De Souza C., Flinn I. W., Hughes T. P. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet Oncology, 2011, vol. 12, no. 9, pp. 841-851. https://doi.org/10.1016/S1470-2045(11)70201-7; Tan F. H., Putoczki T. L., Stylli S. S., Luwor R. B. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. OncoTargets and Therapy, 2019, vol. 12, pp. 635-645. https://doi.org/10.2147/OTT.S189391; O'Hare T. A decade of nilotinib and dasatinib: From in vitro studies to first-line tyrosine kinase inhibitors. Cancer Research, 2016, vol. 76, no. 20, pp. 5911-5913. https://doi.org/10.1158/0008-5472.CAN-16-2483; Brummendorf T. H., Cortes J. E., de Souza C. A., Guilhot F., Duvillie L., ., Gambacorti-Passerini C. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: Results from the 24-month follow-up of the BELA trial. British Journal of Haematology, 2015, vol. 168, no. 1, pp. 69-81. https://doi.org/10.1111/bjh.13108; Bhullar K. S., Lagaron N. O., McGowan E. M., Parmar I., Jha A., Rupasinghe H. P. V. Kinase-targeted cancer therapies: progress, challenges and future directions. Molecular Cancer, 2018, vol. 17, art. 48. Available at: https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-018-0804-2 (accessed 07.08.2023). https://doi.org/10.1186/s12943-018-0804-2; Koroleva E. V., Ignatovich Zh. I., Sinyutich Yu. V., Gusak K. N. Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity. Russian Journal of Organic Chemistry, 2016, vol. 52, no. 2, pp. 139-177. https://doi.org/10.1134/S1070428016020019; Patel A. B., O'Hare T., Deininger M. W. Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors. Hematoogy/Oncology Clinics of North America, 2017, vol. 31, no. 4, pp. 589-612. https://doi.org/10.1016/j.hoc.2017.04.007; Liu J., Zhang Y., Huang H., Lei X., Tang G., ., Peng J. Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation. Chemical Biology and Drug Design, 2021, vol. 97, no. 3, pp. 649-664. https://doi.org/10.1111/cbdd.13801; Trott O., Olson A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 2010. vol. 31, no. 2, pp. 455-461. https://doi.org/10.1002/jcc.21334; Durrant J. D., McCammon J. A. NNScore 2.0: A neural-network receptor-ligand scoring function. Journal of Chemical Information and Modeling, 2011, vol. 51, no. 11, pp. 2897-2903. https://doi.org/+-10.1021/ci2003889; Wójcikowski M., Ballester P. J., Siedlecki P. Performance of machine-learning scoring functions in structure-based virtual screening. Scientific Reports, 2017, vol. 7, no. 1, pp. 1-10.; Hinton G. E., Salakhutdinov R. R. Reducing the dimensionality of data with neural networks. Science, 2006, vol. 313, no. 5786, pp. 504-507.; Hwang M., Qian Y., Wu C., Jiang W. C., Wang D., ., Hwang K. S. A local region proposals approach to instance segmentation for intestinal polyp detection. International Journal of Machine Learning and Cybernetics, 2023, vol. 14, no. 5, pp. 1591-1603.; Huang A., Ju X., Lyons J., Murnane D., Pettee M., Reed L. Heterogeneous Graph Neural Network for Identifying Hadronically Decayed Tau Leptons at the High Luminosity LHC. Available at: https://arxiv.org/pdf/2301.00501.pdf (accessed 07.08.2023).; Weininger D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. Journal of Chemical Information and Computer Sciences, 1988, vol. 28, no. 1, pp. 31-36. https://doi.org/10.1021/ci00057a005; Weininger D., Weininger A., Weininger, J. L. SMILES. 2. Algorithm for generation of unique SMILES notation. Journal of Chemical Information and Computer Sciences, 1989, vol. 29, no. 2, pp. 97-101.; O'Boyle N. M. Towards a Universal SMILES representation-A standard method to generate canonical SMILES based on the InChI. Journal of Cheminformatics, 2012, vol. 4, art. 22, pp. 1-14.; Kim S., Chen J., Cheng T., Gindulyte A., He J., ., Bolton E. E. PubChem 2019 update: improved access to chemical data. Nuclear Acids Research, 2019, vol. 47(D1), pp. D1102-D1109.; Ho Y., Wookey S. The real-world-weight cross-entropy loss function: Modeling the costs of mislabeling. IEEE Access, 2019, vol. 8, pp. 4806-4813.; Kingma D. P., Ba J. Adam: A Method for Stochastic Optimization, 2014. Available at: https://arxiv.org/pdf/1412.6980.pdf (accessed 07.08.2023).; Landrum G. RDKit: A Software Suite for Cheminformatics, Computational Chemistry, and Predictive Modeling, 2013. Available at: https://www.rdkit.org/RDKit_Overview.pdf (accessed 07.08.2023).; Palacio-Rodríguez K., Lans I., Cavasotto C. N., Cossio P. Exponential consensus ranking improves the outcome in docking and receptor ensemble docking. Scientific Reports, 2019, vol. 9, no. 1, art. 5142. Available at: https://www.nature.com/articles/s41598-019-41594-3 (accessed 07.08.2023). https://doi.org/10.1038/s41598-019-41594-3; Lipinski C. A. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies, 2004, vol. 1, no. 4, pp. 337-341.; Verma J., Khedkar V. M., Coutinho E. C. 3D-QSAR in drug design-a review. Current Topics in Medicinal Chemistry, 2010, vol. 10, no. 1, pp. 95-115. https://doi.org/10.2174/156802610790232260; Kuseva C., Schultz T. W., Yordanova D., Tankova K., Kutsarova S., ., Mekenyan O. G. The implementation of RAAF in the OECD QSAR Toolbox. Regulatory Toxicology and Pharmacology, 2019, vol. 105, pp. 51-61. https://doi.org/10.1016Zj.yTtph.2019.03.018; https://inf.grid.by/jour/article/view/1259